10x Genomics vs Cradle Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience, and immunology.
About
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabling researchers to analyze gene expression across thousands of individual cells simultaneously—a capability that transformed cell biology, immunology, and cancer research. The Visium Spatial Gene Expression platform extended this to map gene expression within intact tissue architecture.\n\n10x Genomics' instruments and consumables are used by leading academic research centers, pharmaceutical companies, and translational medicine teams to profile the cellular composition of tumors, map the nervous system, characterize immune responses, and develop cell therapies. The company reported full-year 2025 revenue of $642.8 million, up from $610.8 million in 2024, and guides to $600–$625 million for 2026 amid cautious biotech funding conditions.\n\nThe company is transitioning toward a broader multi-omics portfolio including ATAC-seq, protein detection, and spatial multi-omics, while defending market position against competition from Parse Biosciences, Vizgen, and others. Despite near-term funding headwinds in academic markets, 10x Genomics remains a foundational infrastructure provider for the cell atlas era of biology.
Cradle provides an AI platform for protein engineering that accelerates the design of improved enzymes, antibodies, and other biologics for industrial and therapeutic use.
About
Cradle Bio is an AI protein engineering company founded in 2021 in Amsterdam, having raised $73M to build an AI-powered protein design platform. The platform combines generative AI with wet-lab experimentation to accelerate the iterative process of engineering proteins with improved stability, activity, and manufacturability. Cradle's technology enables researchers to design thousands of protein variants computationally and prioritize those most likely to succeed in laboratory validation, compressing protein engineering timelines from years to months. The company serves both industrial biotechnology customers engineering enzymes for biomanufacturing and pharmaceutical companies developing next-generation antibody therapeutics. Cradle partners with contract research organizations and biopharmaceutical companies to integrate AI-assisted protein design into existing discovery workflows. The company has been recognized as a leader in the European deep tech ecosystem and positions protein engineering AI as enabling a new era of designed biologics for medicine and sustainable manufacturing.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.